Business
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-dri
About this update from Ibio, Inc.
[{"type":"image","alt":"iBio, Inc.","displaySize":"","headline":null,"caption":"iBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1KqEAeSsXDrzRh_W7Gd9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOA--/https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac","width":300,"height":170},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1KqEAeSsXDrzRh_W7Gd9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOA--/https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac","width":300,"height":170}},"lazy":false},{"type":"text","content":"Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia","length":93,"tagName":"p"},{"type":"text","content":"Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody ","length":169,"tagName":"p"},{"type":"text","content":"Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% ","length":166,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today reported financial results for the third quarter ended Mar. 31, 2026, and provided a corporate update on its progress.","length":297,"tagName":"p"},{"type":"text","content":"“This last quarter was marked by significant advancement across our full pipeline. Most importantly, we received the clearance to enter the clinic with IBIO-600, which we believe has best-in-class potential due to its ability to preserve lean mass and improve body composition in obesity,” said Martin Brenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “We also presented new data for IBIO-610 demonstrating targeted reduction of total and visceral fat in obese non-human primates (NHPs) and expanded our pipeline with our selective bispecific antibody designed to block Activin A, GDF8 (myostatin) and GDF11, potentially to treat PH-HFpEF, which...